M

Metagenomi Inc
NASDAQ:MGX

Watchlist Manager
Metagenomi Inc
NASDAQ:MGX
Watchlist
Price: 1.66 USD 1.22% Market Closed
Market Cap: 62.3m USD

Operating Margin
Metagenomi Inc

-298.5%
Current
-203%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-298.5%
=
Operating Profit
-92.3m
/
Revenue
30.9m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Metagenomi Inc
NASDAQ:MGX
62.3m USD
-298%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
393.8B USD
33%
US
Amgen Inc
NASDAQ:AMGN
174.5B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
150.9B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.6B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.8B USD
28%
AU
CSL Ltd
ASX:CSL
84.9B AUD
26%
NL
argenx SE
XBRU:ARGX
44.9B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.2B USD
8%
No Stocks Found

Metagenomi Inc
Glance View

Market Cap
62.3m USD
Industry
Biotechnology

Metagenomi Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Emeryville, California and currently employs 223 full-time employees. The company went IPO on 2024-02-09. Metagenomi, Inc. is a precision genetic medicine company. The firm is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). The company has also developed an expansive and modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. Its platform enables it to rapidly and effectively find, screen, and select tools with the highest targetability, specificity, and efficiency in order to develop them into genetic medicine.

MGX Intrinsic Value
2.12 USD
Undervaluation 22%
Intrinsic Value
Price
M
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-298.5%
=
Operating Profit
-92.3m
/
Revenue
30.9m
What is the Operating Margin of Metagenomi Inc?

Based on Metagenomi Inc's most recent financial statements, the company has Operating Margin of -298.5%.

Back to Top